First Bank & Trust Has $202,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

First Bank & Trust grew its position in Agilent Technologies, Inc. (NYSE:A) by 11.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,502 shares of the medical research company’s stock after buying an additional 150 shares during the quarter. First Bank & Trust’s holdings in Agilent Technologies were worth $202,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Handelsbanken Fonder AB boosted its holdings in shares of Agilent Technologies by 8.0% during the fourth quarter. Handelsbanken Fonder AB now owns 143,215 shares of the medical research company’s stock worth $19,240,000 after purchasing an additional 10,636 shares during the period. Ieq Capital LLC boosted its holdings in shares of Agilent Technologies by 52.3% during the fourth quarter. Ieq Capital LLC now owns 25,849 shares of the medical research company’s stock worth $3,473,000 after purchasing an additional 8,879 shares during the period. Kentucky Retirement Systems Insurance Trust Fund boosted its holdings in shares of Agilent Technologies by 35.6% during the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 11,714 shares of the medical research company’s stock worth $1,574,000 after purchasing an additional 3,076 shares during the period. Cardinal Capital Management boosted its holdings in shares of Agilent Technologies by 0.3% during the fourth quarter. Cardinal Capital Management now owns 68,764 shares of the medical research company’s stock worth $9,255,000 after purchasing an additional 213 shares during the period. Finally, Venturi Wealth Management LLC boosted its holdings in shares of Agilent Technologies by 53.9% during the fourth quarter. Venturi Wealth Management LLC now owns 805 shares of the medical research company’s stock worth $108,000 after purchasing an additional 282 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently commented on A shares. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Bank of America reduced their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Sanford C. Bernstein reduced their target price on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research note on Tuesday, November 26th. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $135.00 to $145.00 in a research note on Monday, February 10th. Finally, Wells Fargo & Company reduced their target price on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $144.38.

Agilent Technologies Trading Down 0.3 %

NYSE:A opened at $136.74 on Friday. Agilent Technologies, Inc. has a 12 month low of $124.16 and a 12 month high of $155.35. The firm has a market cap of $39.01 billion, a price-to-earnings ratio of 30.94, a P/E/G ratio of 3.66 and a beta of 1.07. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average is $141.04 and its 200-day moving average is $139.28.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The business had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same quarter in the previous year, the firm posted $1.38 earnings per share. Agilent Technologies’s revenue was up .8% compared to the same quarter last year. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.56 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.40%.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. The trade was a 4.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.